• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Elevated NT-proBNP predicts unfavorable outcomes in patients with acute ischemic stroke after thrombolytic therapy
Few studies correlated n-terminal pro-brain natriuretic peptide (NT-proBNP) with early neurological deterioration (END) and prognosis of acute ischaemic stroke (AIS) patients with rt-PA intravenous thrombolysi...
Source: BMC Neurology - May 23, 2023 Category: Neurology Authors: Zhuang Zhu, Bilal Muhammad, Bo Du, Ning Gu, Tian-Yue Meng, Shu Kan, Ying-Feng Mu, Yan-Bo Cheng, Shi-Guang Zhu and De-Qin Geng Tags: Research Source Type: research

The effects of the coronavirus disease pandemic on intravenous thrombolytic therapy among patients with acute ischemic stroke in Dalian, China
We investigated the influence of the coronavirus disease 2019 (COVID-19) pandemic on the number of patients with acute ischemic stroke who received intravenous thrombolytic therapy (ITT) in Dalian, China, in 2...
Source: BMC Neurology - January 9, 2023 Category: Neurology Authors: Xin Pan, Shubei Ma, Xiaowen Sui, Lili Xie, Furong Li, Zhengping Cheng, Li Cui and Hongling Zhao Tags: Research Source Type: research

Efficacy and safety of cinepazide maleate injection in patients with acute ischemic stroke: a multicenter, randomized, double-blind, placebo-controlled trial
Ischemic stroke is a leading cause of morbidity and mortality. Thrombolytic therapy improves disability and survival rates; however, to be effective, it must be given within 4.5  h of onset. Moreover, thromboly...
Source: BMC Neurology - July 14, 2020 Category: Neurology Authors: Jun Ni, Huisheng Chen, Guofang Chen, Yong Ji, Fei Yi, Zhuobo Zhang, Yi Yang, Jin Wu, Xueli Cai, Bei Shao, Jianfeng Wang, Yafang Liu, Deqin Geng, Xinhui Qu, Xiaohong Li, Yan Wei & hellip; Tags: Research article Source Type: research

Outcomes of thrombolytic therapy in acute ischemic stroke: mothership, drip-and-ship, and ship-and-drip paradigms
Chulalongkorn Stroke Center is a comprehensive stroke center (CSC) located in Bangkok, Thailand. Our stroke network consists of different levels of spoke hospitals, ranging from community hospitals where throm...
Source: BMC Neurology - February 3, 2020 Category: Neurology Authors: Naruchorn Kijpaisalratana, Aurauma Chutinet, Wasan Akarathanawat, Pakkawan Vongvasinkul and Nijasri C. Suwanwela Tags: Research article Source Type: research

Intravenous thrombolytic therapy for acute ischemic stroke in Hubei, China: a survey of thrombolysis rate and barriers
Rates of thrombolysis in most countries are well below best practice benchmarks. We aimed to investigate thrombolysis utilization and its associated factors in acute ischemic stroke (AIS) patients in Hubei pro...
Source: BMC Neurology - August 22, 2019 Category: Neurology Authors: Yanfeng Zhou, Shijiao Yan, Xingyue Song, Yanhong Gong, Wenzhen Li, Mengdie Wang, Xiaoxv Yin, Bo Hu and Zuxun Lu Tags: Research article Source Type: research

In vitro examination of the thrombolytic efficacy of tenecteplase and therapeutic ultrasound compared to rt-PA
Optimizing thrombolytic therapy is vital for improving stroke outcomes. We aimed to develop standardized thrombolysis conditions to evaluate the efficacy of tenecteplase (TNK) compared to the current gold stan...
Source: BMC Neurology - August 2, 2019 Category: Neurology Authors: Tobias Fr ühwald, Ulrich Gärtner, Nils Stöckmann, Jan-Henning Marxsen, Carolin Gramsch and Florian C. Roessler Tags: Research article Source Type: research

Status of prehospital delay and intravenous thrombolysis in the management of acute ischemic stroke in Nepal
The objective of this...
Source: BMC Neurology - July 9, 2019 Category: Neurology Authors: Gaurav Nepal, Jayant Kumar Yadav, Babin Basnet, Tirtha Man Shrestha, Ghanshyam Kharel and Rajeev Ojha Tags: Research article Source Type: research

Clinical and radiological factors associated with unfavorable outcome after intravenous thrombolysis in patients with mild ischemic stroke
A significant proportion of patients with mild ischemic stroke become disabled despite receiving intravenous thrombolytic therapy. The purpose of this study was to assess the clinical and radiological factors ...
Source: BMC Neurology - March 15, 2018 Category: Neurology Authors: Dae-Hyun Kim, Deok-Soo Lee, Hyun-Wook Nah and Jae-Kwan Cha Tags: Research article Source Type: research

Increase in national intravenous thrombolysis rates for ischaemic stroke between 2005 and 2012: is bigger better?
Intravenous thrombolytic therapy after ischaemic stroke significantly reduces mortality and morbidity. Actual thrombolysis rates are disappointingly low in many western countries. It has been suggested that hi...
Source: BMC Neurology - April 21, 2016 Category: Neurology Authors: S. Scherf, M. Limburg, R. Wimmers, I. Middelkoop and H. Lingsma Source Type: research

The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke
Background: Alteplase is the only approved thrombolytic agent for acute ischaemic stroke. The overall benefit from alteplase is substantial, but some evidence indicates that alteplase also has negative effects on the ischaemic brain. Tenecteplase may be more effective and less harmfull than alteplase, but large randomised controlled phase 3 trials are lacking. The Norwegian Tenecteplase Stroke Trial (NOR-TEST) aims to compare efficacy and safety of tenecteplase vs. alteplase. Methods: NOR-TEST is a multi-centre PROBE (prospective randomised, open-label, blinded endpoint) trial designed to establish superiority of tenectepl...
Source: BMC Neurology - May 15, 2014 Category: Neurology Authors: Nicola LogalloChristopher KvistadAliona NacuHalvor NaessUlrike Waje-AndreassenJörg AsmussAnne Hege AamodtChristian LundMartin KurzOle Morten RønningRolf SalvesenTitto IdiculaLars Thomassen Source Type: research